Statin use and uterine fibroid risk in hyperlipidemia patients

a nested case-control study

Mostafa A. Borahay, Xiao Fang, Jacques G. Baillargeon, Gokhan S. Kilic, Darren F. Boehning, Yong Fang Kuo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors primarily used for treatment of hyperlipidemia. Recently, they have been shown to inhibit proliferation of uterine fibroid cells and inhibit tumor growth in fibroid animal models. Objective We sought to examine the association between statin use and the risk of uterine fibroids and fibroid-related symptoms in a nationally representative sample of commercially insured women diagnosed with hyperlipidemia. Study Design We performed a nested case-control study of >190,000 women enrolled in one of the nation's largest commercial health insurance programs. From a cohort of women aged 18-65 years diagnosed with hyperlipidemia from January 2004 through March 2011, we identified 47,713 cases (women diagnosed with uterine fibroids) and 143,139 controls (women without uterine fibroids) matched at a 1:3 ratio on event/index date (month and year) and age (±1 year). We used conditional and unconditional logistic regression to calculate odds ratios and 95% confidence intervals for the risk of uterine fibroids and fibroid-related symptoms associated with prior use of statins. Results Exposure to statins within 2 years before the event/index date was associated with a decreased risk of uterine fibroids (odds ratio, 0.85; 95% confidence interval, 0.83–0.87). In a separate subanalysis restricted to cases, statin users had a lower likelihood of having menorrhagia (odds ratio, 0.88; 95% confidence interval, 0.84–0.91), anemia (odds ratio, 0.84; 95% confidence interval, 0.79–0.88), or pelvic pain (odds ratio, 0.85; 95% confidence interval, 0.81–0.91) and of undergoing myomectomy (odds ratio, 0.76; 95% confidence interval, 0.66–0.87) compared to nonusers. Conclusion The use of statins was associated with a lower risk of uterine fibroids and fibroid-related symptoms. Further studies, including randomized controlled trials, may be warranted.

Original languageEnglish (US)
Pages (from-to)750.e1-750.e8
JournalAmerican Journal of Obstetrics and Gynecology
Volume215
Issue number6
DOIs
StatePublished - Dec 1 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Leiomyoma
Hyperlipidemias
Case-Control Studies
Odds Ratio
Confidence Intervals
Uterine Myomectomy
Menorrhagia
Pelvic Pain
Health Insurance
Anemia
Oxidoreductases
Randomized Controlled Trials
Animal Models
Logistic Models

Keywords

  • fibroids
  • leiomyoma
  • menorrhagia
  • pelvic pain
  • statins

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Statin use and uterine fibroid risk in hyperlipidemia patients : a nested case-control study. / Borahay, Mostafa A.; Fang, Xiao; Baillargeon, Jacques G.; Kilic, Gokhan S.; Boehning, Darren F.; Kuo, Yong Fang.

In: American Journal of Obstetrics and Gynecology, Vol. 215, No. 6, 01.12.2016, p. 750.e1-750.e8.

Research output: Contribution to journalArticle

@article{cb63e6069ea74409bd6bdfb6caac27bc,
title = "Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study",
abstract = "Background Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors primarily used for treatment of hyperlipidemia. Recently, they have been shown to inhibit proliferation of uterine fibroid cells and inhibit tumor growth in fibroid animal models. Objective We sought to examine the association between statin use and the risk of uterine fibroids and fibroid-related symptoms in a nationally representative sample of commercially insured women diagnosed with hyperlipidemia. Study Design We performed a nested case-control study of >190,000 women enrolled in one of the nation's largest commercial health insurance programs. From a cohort of women aged 18-65 years diagnosed with hyperlipidemia from January 2004 through March 2011, we identified 47,713 cases (women diagnosed with uterine fibroids) and 143,139 controls (women without uterine fibroids) matched at a 1:3 ratio on event/index date (month and year) and age (±1 year). We used conditional and unconditional logistic regression to calculate odds ratios and 95{\%} confidence intervals for the risk of uterine fibroids and fibroid-related symptoms associated with prior use of statins. Results Exposure to statins within 2 years before the event/index date was associated with a decreased risk of uterine fibroids (odds ratio, 0.85; 95{\%} confidence interval, 0.83–0.87). In a separate subanalysis restricted to cases, statin users had a lower likelihood of having menorrhagia (odds ratio, 0.88; 95{\%} confidence interval, 0.84–0.91), anemia (odds ratio, 0.84; 95{\%} confidence interval, 0.79–0.88), or pelvic pain (odds ratio, 0.85; 95{\%} confidence interval, 0.81–0.91) and of undergoing myomectomy (odds ratio, 0.76; 95{\%} confidence interval, 0.66–0.87) compared to nonusers. Conclusion The use of statins was associated with a lower risk of uterine fibroids and fibroid-related symptoms. Further studies, including randomized controlled trials, may be warranted.",
keywords = "fibroids, leiomyoma, menorrhagia, pelvic pain, statins",
author = "Borahay, {Mostafa A.} and Xiao Fang and Baillargeon, {Jacques G.} and Kilic, {Gokhan S.} and Boehning, {Darren F.} and Kuo, {Yong Fang}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.ajog.2016.06.036",
language = "English (US)",
volume = "215",
pages = "750.e1--750.e8",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Statin use and uterine fibroid risk in hyperlipidemia patients

T2 - a nested case-control study

AU - Borahay, Mostafa A.

AU - Fang, Xiao

AU - Baillargeon, Jacques G.

AU - Kilic, Gokhan S.

AU - Boehning, Darren F.

AU - Kuo, Yong Fang

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors primarily used for treatment of hyperlipidemia. Recently, they have been shown to inhibit proliferation of uterine fibroid cells and inhibit tumor growth in fibroid animal models. Objective We sought to examine the association between statin use and the risk of uterine fibroids and fibroid-related symptoms in a nationally representative sample of commercially insured women diagnosed with hyperlipidemia. Study Design We performed a nested case-control study of >190,000 women enrolled in one of the nation's largest commercial health insurance programs. From a cohort of women aged 18-65 years diagnosed with hyperlipidemia from January 2004 through March 2011, we identified 47,713 cases (women diagnosed with uterine fibroids) and 143,139 controls (women without uterine fibroids) matched at a 1:3 ratio on event/index date (month and year) and age (±1 year). We used conditional and unconditional logistic regression to calculate odds ratios and 95% confidence intervals for the risk of uterine fibroids and fibroid-related symptoms associated with prior use of statins. Results Exposure to statins within 2 years before the event/index date was associated with a decreased risk of uterine fibroids (odds ratio, 0.85; 95% confidence interval, 0.83–0.87). In a separate subanalysis restricted to cases, statin users had a lower likelihood of having menorrhagia (odds ratio, 0.88; 95% confidence interval, 0.84–0.91), anemia (odds ratio, 0.84; 95% confidence interval, 0.79–0.88), or pelvic pain (odds ratio, 0.85; 95% confidence interval, 0.81–0.91) and of undergoing myomectomy (odds ratio, 0.76; 95% confidence interval, 0.66–0.87) compared to nonusers. Conclusion The use of statins was associated with a lower risk of uterine fibroids and fibroid-related symptoms. Further studies, including randomized controlled trials, may be warranted.

AB - Background Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors primarily used for treatment of hyperlipidemia. Recently, they have been shown to inhibit proliferation of uterine fibroid cells and inhibit tumor growth in fibroid animal models. Objective We sought to examine the association between statin use and the risk of uterine fibroids and fibroid-related symptoms in a nationally representative sample of commercially insured women diagnosed with hyperlipidemia. Study Design We performed a nested case-control study of >190,000 women enrolled in one of the nation's largest commercial health insurance programs. From a cohort of women aged 18-65 years diagnosed with hyperlipidemia from January 2004 through March 2011, we identified 47,713 cases (women diagnosed with uterine fibroids) and 143,139 controls (women without uterine fibroids) matched at a 1:3 ratio on event/index date (month and year) and age (±1 year). We used conditional and unconditional logistic regression to calculate odds ratios and 95% confidence intervals for the risk of uterine fibroids and fibroid-related symptoms associated with prior use of statins. Results Exposure to statins within 2 years before the event/index date was associated with a decreased risk of uterine fibroids (odds ratio, 0.85; 95% confidence interval, 0.83–0.87). In a separate subanalysis restricted to cases, statin users had a lower likelihood of having menorrhagia (odds ratio, 0.88; 95% confidence interval, 0.84–0.91), anemia (odds ratio, 0.84; 95% confidence interval, 0.79–0.88), or pelvic pain (odds ratio, 0.85; 95% confidence interval, 0.81–0.91) and of undergoing myomectomy (odds ratio, 0.76; 95% confidence interval, 0.66–0.87) compared to nonusers. Conclusion The use of statins was associated with a lower risk of uterine fibroids and fibroid-related symptoms. Further studies, including randomized controlled trials, may be warranted.

KW - fibroids

KW - leiomyoma

KW - menorrhagia

KW - pelvic pain

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=84995685526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995685526&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2016.06.036

DO - 10.1016/j.ajog.2016.06.036

M3 - Article

VL - 215

SP - 750.e1-750.e8

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -